Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 7, 2013, Pages 839-848

  Mathieu, Claudia ^a   Rioux, Gervais ^a   Dumas, Marie Christine ^a   Leclerc, Denis ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Influenza; Innate immunity; Nanoparticles; Nanotubes; Papaya mosaic virus; Pneumococcus pneumoniae; Virus like particles

Indexed keywords

INFLUENZA; INNATE IMMUNITY; MOSAIC VIRUS; PNEUMOCOCCUS PNEUMONIAE; VIRUS-LIKE PARTICLES;

BIOTERRORISM; IMMUNE SYSTEM; MAMMALS; NANOPARTICLES; NANOTUBES;

VIRUSES;

COAT PROTEIN; NANOPARTICLE; SINGLE STRANDED RNA; UNCLASSIFIED DRUG; VIRUS LIKE NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PNEUMONIA; BIOLOGICAL WARFARE; CONTROLLED STUDY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS A; INNATE IMMUNITY; LYMPHOCYTE; MACROPHAGE; MONOCYTE; MORBIDITY; MOUSE; NEUTROPHIL; NONHUMAN; PANDEMIC; PLANT VIRUS; PROTECTION; STREPTOCOCCUS PNEUMONIAE; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS; PAPAYA MOSAIC VIRUS; STREPTOCOCCUS PNEUMONIAE;

INFLUENZA; INNATE IMMUNITY; NANOPARTICLES; NANOTUBES; PAPAYA MOSAIC VIRUS; PNEUMOCOCCUS PNEUMONIAE; VIRUS LIKE PARTICLES;

ANIMALS; CHEMOKINES; HUMANS; IMMUNITY, INNATE; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED BALB C; MOSAIC VIRUSES; NANOPARTICLES; ORTHOMYXOVIRIDAE INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS;

EID: 84884289204     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.02.009     Document Type: Article

References (43)

1. Stewart A.M., Cox M.A. State law and influenza vaccination of health care personnel. Vaccine 2012, 31:827-832.
2. Chertow D.S., Memoli M.J. Bacterial coinfection in influenza: a grand round review. JAMA 2013, 309:275-282.
3. León A.J., Banner D., Xu L., Ran L., Peng Z., Yi K., et al. Sequencing, annotation and characterization of the influenza ferret infectome. J Virol 2013, 87:1957-1966.
4. Teijaro J.R., Walsh K.B., Cahalan S., Fremgen D.M., Roberts E., Scott F., et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011, 146:980-991.
5. La Gruta N.L., Kedzierska K., Stambas J., Doherty P.C. A question of self preservation: immunopathology in influenza virus infection. Immunol Cell Biol 2007, 85:85-92.
6. Gack M.U., Albrecht R.A., Urano T., Inn K.S., Huang I.C., Camero E., et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009, 5:439-449.
7. Mibayashi M., Martinez-Sobrido L., Loo Y.M., Cardenas W.B., Gale M., Gastra-Sastre A. Inhibition of retinoic acid-inducible gene mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 2007, 81:514-524.
8. Bergmann M., Garcia-Sastre A., Carnero E., Pehamberger H., Wolff K., Palese P., et al. Influenza virus NS1 protein counteracts PKR476 mediated inhibition of replication. J Virol 2000, 74:6203-6206.
9. Hatada E., Saito S., Fukuda R. Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. J Virol 1999, 73:2425-2433.
10. Lu Y., Wambach M., Katze M.G., Krug R.M. Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology 1995, 214:222-228.
11. Talon J., Horvath C.M., Polley R., Basler C.F., Muster T., Palese P., et al. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol 2000, 74:7989-7996.
12. Wang X., Li M., Zheng H., Muster T., Palese P.ç., Beg A.A., et al. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol 2000, 74:11566-11573.
13. Norton E.B., Clements J.D., Voss T.G., Cardenas-Freytag L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol 2010, 84:2983-2995.
14. Tuvim M.J., Evans S.E., Clement C.G., Dickey B.F., Gilbert B.E. Augmented lung inflammation protects against influenza A pneumonia. PLoS One 2009, 4:e4176.
15. Clement C., Evans S., Evans C., Hawke D., Kobayashi R., Reynolds P.R., et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 2008, 177:1322-1352.
16. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.-E., Koukavica I., Baz M., et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26:3395-3403.
17. Denis J., Majeau N., Acosta-Ramirez E., Savard C., Bedard M.-C., Simard S., et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization. Virology 2007, 363:59-68.
18. Lacasse P., Denis J., Lapointe R., Leclerc D., Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J Virol 2008, 82:785-794.
19. Leclerc D., Beauseigle D., Denis J., Morin H., Pare C., Lamarre A., et al. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J Virol 2007, 81:1319-1326.
20. Acosta-Ramírez E., Pérez-Flores R., Majeau N., Pastelin-Palacios R., Gil-Cruz C., Ramírez-Saldaña M., et al. Translating innate response into long-lasting antibody response by the intrinsic antigen-adjuvant properties of papaya mosaic virus. Immunology 2008, 124:186-197.
21. Savard C., Guérin A., Drouin K., Bolduc M., Laliberté-Gagné M.-E., Dumas M.-C., et al. Improvement of the trivalent inactivated Flu vaccine using PapMV nanoparticles. PLoS One 2011, 6:e21522.
22. Rioux G., Babin C., Majeau N., Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. PLoS One 2012, 7:e31925.
23. Tremblay M.-H., Majeau N., Laliberté-Gagné M.-E., Lecours K., Morin H., Bolduc M., et al. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J 2006, 273:14-25.
24. Kohlmeier J.E., Woodland D.L. Immunity to respiratory viruses. Annu Rev Immunol 2009, 27:61-82.
25. Vareille M., Kieninger E., Edwards M., Regamey N. The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev 2011, 24:210-239.
26. Stuart-Harris C.H. A neurotropic strain of human influenza virus. Lancet 1939, 1:497-499.
27. Azoulay-Dupuis E., Vallee E., Bedos J.P., Muffat-Joly M., PocidalL J.J. Lactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. J Antimicrobial Chemother 1992, 29:677-685.
28. Evans S.E., Scott B.L., Clement C.G., Larson D.T., Kontoyiannis D., Lewis R.E., et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Crit Care Med 2010, 42:40-50.
29. Rijneveld A., de Vos A., Florquin S., Verbeek J., van der Poll T. CD11b limits bacterial outgrowth and dissemination during murine pneumococcal pneumonia. JID 2005, 191:1755-1815.
30. Sun K., Salmon S., Lotz S., Metzger D. Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect Immun 2007, 75:1196-1398.
31. Miyata R., van Eeden S. The innate and adaptive immune response induced by alveolar macrophages exposed to ambient particulate matter. Toxicol Appl Pharmacol 2011, 257:209-235.
32. Tuvim M., Gilbert B., Dickey B., Evans S. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One 2012, 7:e30596.
33. Mark D.W., Ashley L.S., Chandra A.I., Peter B.D., Sally R.S. CXCR2 Is required for neutrophil recruitment to the lung during influenza virus infection, but is not essential for viral Clearan20. Lillard JW. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood 2002, 101:807-814.
34. Lillard J.W. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood 2002, 101:807-814.
35. Lee E., Lee Z.-H., Song Y. CXCL10 and autoimmune diseases. Autoimmun Rev 2009, 8:379-462.
36. Rijavec M., Volarevic S., Osolnik K., Kosnik M., Korosec P. Natural killer T cells in pulmonary disorders. Respir Med 2011, 105(Suppl. 1):S20-S25.
37. Heil F., Ahmad-Nejad P., Hemmi H., Hochrein H., Ampenberger F., Gellert T., et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003, 33:2987-3084.
38. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
39. Desmet C.J., Ishii K.J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012, 12:479-491.
40. Honko A., Mizel S.B. Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect Immun 2004, 72:6676-6679.
41. Munoz N., Van Maele L., Marques J.M., Rial A., Sirard J.C., et al. Mucosal admonistration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun 2010, 78:4226-4233.
42. Abdul-Careem M., Firoz Mian M., Gillgrass A., Chenoweth M., Barra N., Chan T., et al. FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice. Antiviral Res 2011, 92:346-401.
43. Mitchell R.W., Mona D., Patrick B., Tesfaldet T., Kevan L.H. Innate immunity to influenza virus: implications for future therapy. Expert Rev Clin Immunol 2008, 4:497-514.